...
首页> 外文期刊>Japanese journal of clinical oncology. >Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.
【24h】

Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma.

机译:分化型甲状腺癌中免疫组化CD147和MMP-2表达的临床病理评价。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: CD147 is one of the molecules involved in regulating the expression of matrix metalloproteinases (MMPs). The goal of this study was to analyze the expression levels of CD147 and MMP-2 in differentiated thyroid carcinomas (DTCs) tissues, as well as their associations with the clinicopathologic features of DTC patients. METHODS: CD147 and MMP-2 expression in 156 patients who underwent operation for DTC (100 with papillary thyroid carcinomas and 56 with follicular thyroid carcinomas) were examined by immunostaining on paraffin-embedded tumor specimens. The Spearman correlation was calculated between the expression levels of CD147 and MMP-2 in DTC tissues. Then, the association of their expression with clinicopathologic characteristics was analyzed. RESULTS: CD147 and MMP-2 were expressed mainly in cancerous lesions, but also expressed in some normal tissues. A total of 55 and 58 in 156 (35.26 and 37.18%, respectively) cases showed low CD147- and MMP-2-positive expression; 52 and 50 in 156 (33.33 and 32.05%, respectively) cases showed intermediate CD147- and MMP-2-positive expression and 49 and 48 in 156 (31.41 and 30.77%, respectively) cases showed high CD147- and MMP-2-positive expression. The Spearman analysis indicated that the expression level of CD147 was positively correlated with that of MMP-2 significantly (rs = 0.86, P = 0.02). Positive CD147 and MMP-2 immunostaining associated significantly with extrathyroidal invasion (P = 0.02, 0.03), lymph node metastasis (P = 0.01, 0.01) and depth of tumor invasion (P < 0.01, =0.01). CONCLUSIONS: The results have been demonstrated that the expression of CD147 and MMP-2 may be an important feature of DTC. The detection of these two markers may increase the ability of clinicians to investigate the progression of DTC patients.
机译:目的:CD147是调控基质金属蛋白酶(MMPs)表达的分子之一。这项研究的目的是分析CD147和MMP-2在分化的甲状腺癌(DTC)组织中的表达水平,以及它们与DTC患者的临床病理特征的关系。方法:对石蜡包埋的肿瘤标本进行免疫染色,检查了156例接受DTC手术的患者中CD147和MMP-2的表达(100例甲状腺乳头状癌和56例滤泡性甲状腺癌)。在DTC组织中CD147和MMP-2的表达水平之间计算Spearman相关性。然后,分析了它们的表达与临床病理特征的关系。结果:CD147和MMP-2主要在癌性病变中表达,在某些正常组织中也表达。 156例病例中分别有55例和58例(分别为35.26例和37.18%)显示出低的CD147-和MMP-2阳性表达; 156(分别为33.33和32.05%)病例中的52和50显示中等CD147-和MMP-2阳性表达,156(分别为31.41和30.77%)病例中49和48显示高CD147-和MMP-2阳性表达。 Spearman分析表明,CD147的表达水平与MMP-2的表达呈显着正相关(rs = 0.86,P = 0.02)。阳性CD147和MMP-2免疫染色与甲状腺外侵犯(P = 0.02,0.03),淋巴结转移(P = 0.01,0.01)和肿瘤浸润深度(P <0.01,= 0.01)显着相关。结论:结果表明,CD147和MMP-2的表达可能是DTC的重要特征。这两个标记的检测可能会增加临床医生调查DTC患者病情的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号